Steris PLC
STE: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$214.00 | Ntgsx | Bdqkwnkz |
Narrow-Moat Steris Reports Decent Growth and Record Margin in Fiscal Q3 With Cantel Purchase Pending
Narrow-moat Steris reported decent fiscal third-quarter results that met expectations. We had previously updated our model to account for the pending Cantel Medical acquisition, and we are leaving our $181 fair value estimate unchanged. Shares remain fairly valued following the decline in the stock price at market open, which we attribute to Steris’ announcement of CEO Walt Rosebrough’s retirement.